Juul: The rise of a $38bn e-cigarette phenomenon

Get real time updates directly on you device, subscribe now.

Juul: The rise of a $38bn e-cigarette phenomenon

Image copyright Reuters
Image caption Juul has experienced explosive growth – but will it continue?

Juul has all the qualities of a standard Silicon Valley success – fat profit margins, explosive growth, and even the cultural cachet to make its name a verb.

But the three-year-old start-up is not a simple technology company: it sells addictive e-cigarettes.

Its popularity among teens has provoked a backlash from authorities, and the announcement last month that it would join forces with Altria, which makes Marlboro cigarettes, has only ramped up the controversy.

So how did the firm grow to be worth more than $38bn (£30bn)?

How did the firm start?

Juul shares an origin story with many other Silicon Valley firms.

Founders Adam Bowen, 43, and James Monsees, 38, met in the early 2000s while in graduate school at Stanford University, where they were studying product design.

Smokers themselves, they went looking for a way to make cigarettes less carcinogenic and foul-smelling, and more socially acceptable.

Image copyright AFP/Getty
Image caption Co-founders Adam Bowen (L) and James Monsees (R) are now worth billions, according to Forbes

They set up their company Pax Labs in 2007 and spent about a decade working on vape products, before launching Juul in 2015.

The device, often likened to an unusually long flash drive, heats liquids inserted via a pod, which come in flavours such as tobacco, mint and mango and hold about as much nicotine as a pack of cigarettes.

How big is Juul?

Pax Labs spun out Juul as an independent company in 2017, and since then the firm's growth has been astonishing.

In 2018 alone, Juul expanded from about 225 employees to roughly 1,500, as sales more than tripled, according to analyst estimates.

The firm now claims some 70% of the US e-cigarette market, putting it on track to make what some analysts estimate will be well over $2bn in sales this year.

  • Vaping: Good, bad or not clear?
  • More teens are vaping – why?

Juul also sells in seven countries outside the US, including the UK, Germany and France.

Altria's deal to take a 35% stake in Juul, valued the firm at more than $38bn – more than double the $16bn valuation settled on during its most recent financing round in July.

The deal made Juul's two co-founders billionaires, according to Forbes. It also put their three-year-old start-up on a par with the market cap of publicly listed companies such as Ford and Delta Airlines.

What's unique about Juul?

The company doesn't use the cancer-causing tobacco-burning process of traditional cigarettes.

But in the US, Juul pods deliver more nicotine than many rival e-cigarette brands – a design the firm says was intended to help switch smokers to their products.

That addictive quality is one reason why Juul has caught on.

Analysts also cite Juul's flavours, discreet size and easy-to-use features, while critics blame early advertising campaigns for creating a "cool" factor that appealed to youth.

Investors focused on Juul's financial prospects emphasise that its products are cheaper than cigarettes and have higher profit margins.

Why does this matter?

There are about 38 million adults who smoke cigarettes in the US, according to the Centers for Disease Control and Prevention, though that number is falling. The percentage of adult smokers dropped from almost 21% in 2005 to about 15.5% in 2016.

Just how much of that is due to e-cigarettes isn't entirely clear.

But Juul – which has a stated mission of replacing traditional cigarettes – argues that its growth, alongside an accelerating decline in cigarette sales, is no coincidence.

About 25% to 45% of Juul's sales may be replacing cigarette consumption, Piper Jaffray analysts estimate.

Image copyright AFP

Those trends pose enough of a threat for Altria to pay top dollar.

"Although we think Juul had [Altria] over a barrel, the best decision in our view was for [Altria] to bite the bullet [and] take a stake in Juul rather than face potential downside risk," Bonnie Herzog, a managing director at Wells Fargo Securities wrote in a note to clients.

On a call with investors, Altria boss Howard Willard said he was confident that Juul was worth the price, noting that Altria had been monitoring the firm's growth for some time.

"What continually happened was they exceeded our optimistic growth projections," he said.

So will Juul's growth continue?

The tie-up with Altria should help Juul get its products into more stores in the US and benefit from Altria's lobbying operation.

The firm is also at the start of what is planned to be a major international expansion, after venturing abroad for the first time in 2018.

But there's a lot of uncertainty ahead.

Media playback is unsupported on your device
Media captionSweet tasting e-cigarettes "recruit" children

In the US, where authorities have pronounced e-cigarette use among teens an "epidemic", Juul has announced steps to curb their use among younger buyers, including suspending sales of some of its popular flavours – such as mango, creme and cucumber – in stores.

The firm, which is under investigation by the US Food and Drug Administration (FDA), also shut down social media accounts and pledged $30m towards research as well as youth and parent education.

Abroad, the company faces different regulatory challenges – notably restrictions on nicotine levels in some markets, including the UK, which could make its pods less distinctive compared with rival e-cigarettes.

In the US, Juul sells pods that contain 5% nicotine by weight – higher than many of its competitors – whereas in places such as the EU it is restricted to 1.7%.

And while analysts say the firm's profit margins on its products are well above traditional cigarettes, that's at least in part because they are free of the kinds of taxes levied on traditional tobacco.

Morgan Stanley analyst Pamela Kaufman said at the moment Altria's decision to invest looks strategic, albeit pricey, but there are risks due to the "potential for further FDA regulation".

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.